Effectiveness of Tocilizumab in Patients Hospitalized With COVID-19: A Follow-up of the CORIMUNO-TOCI-1 Randomized Clinical Trial

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

Abani, O., Abbas, A., Abbas, F., Abbas, M., Abbasi, S., Abbass, H., Abbott, A., Abdallah, N., Abdelaziz, A., Abdelfattah, M., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00676-0 · Cited by 1,983

Interleukin-6 receptor antagonists in critically ill patients with Covid-19.

The REMAP-CAP Investigators (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2100433 · Cited by 1,962

Efficacy of Tocilizumab in Patients Hospitalized with Covid-19

Stone, J. H., Frigault, M. J., Serling-Boyd, N. J., Fernandes, A. D., Harvey, L., Foulkes, A. S., Horick, N. K., Healy, B. C., Shah, R., Bensaci, A. M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028836 · Cited by 1,362

Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia

Salama, C., Han, J., Yau, L., Reiss, W. G., Krämer, B., Neidhart, J. D., Criner, G. J., Kaplan‐Lewis, E., Baden, R. P., Pandit, L. M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2030340 · Cited by 1,306

Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial

Hermine, O., Mariette, X., Tharaux, P.-L., Resche-Rigon, M., Porcher, R., Ravaud, P., CORIMUNO-19 Collaborative Group, Bureau, S., Dougados, M., Tibi, A., et al. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.6820 · Cited by 734

Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia

Salvarani, C., Dolci, G., Massari, M., Merlo, D. F., Cavuto, S., Savoldi, L., Bruzzi, P., Boni, F., Braglia, L., Turrà, C., et al. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.6615 · Cited by 696

Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Abaleke, E., Abbas, M. A., Abbasi, S., Abbott, A., Abdelaziz, A., Abdelbadiee, S., Abdelfattah, M., Abdul, B., Rasheed, A. A., Kadir, R. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00149-5 · Cited by 561

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trialPreprint

Horby, P., Campbell, M., Staplin, N., et al. (2021) · medRxiv · doi:10.1101/2021.02.11.21249258 · Cited by 286

Senescence as a therapeutic target in cancer and age-related diseases

McHugh, D., Durán, I., & Gil, J. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01074-4 · Cited by 197

Systematic review and meta-analysis of anakinra, sarilumab, siltuximab and tocilizumab for COVID-19

Khan, F., Stewart, I. D., Fabbri, L., Moss, S., Robinson, K. A., Smyth, A. R., & Jenkins, G. R. (2021) · Thorax · doi:10.1136/thoraxjnl-2020-215266 · Cited by 148

Impact of COVID-19 in solid organ transplant recipients

Danziger‐Isakov, L. A., Blumberg, E. A., Manuel, O., & Sester, M. (2020) · American Journal of Transplantation · doi:10.1111/ajt.16449 · Cited by 139

Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19 – Preliminary reportPreprint

The REMAP-CAP Investigators, Gordon, A. C., Mouncey, P. R., Al-Beidh, F., Rowan, K., Nichol, A., Arabi, Y. M., Annane, D., Beane, A., van Bentum-Puijk, W., et al. (2021) · medRxiv · doi:10.1101/2021.01.07.21249390 · Cited by 130

Interleukin 6 in diabetes, chronic kidney disease, and cardiovascular disease: mechanisms and therapeutic perspectives

Kreiner, F. F., Kraaijenhof, J. M., von Herrath, M., Hovingh, G. K., & von Scholten, B. J. (2022) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2022.2045952 · Cited by 115

Drug Repurposing for COVID-19: A Review and a Novel Strategy to Identify New Targets and Potential Drug Candidates

Rodrigues, L. A., Cunha, R. B., Vassilevskaia, T. D., Viveiros, M., & Cunha, C. V. (2022) · Molecules · doi:10.3390/molecules27092723 · Cited by 91

A Global Picture: Therapeutic Perspectives for COVID-19

Chavda, V. P., Kapadia, C., Soni, S., Prajapati, R., Chauhan, S. C., Yallapu, M. M., & Apostolopoulos, V. (2022) · Immunotherapy · doi:10.2217/imt-2021-0168 · Cited by 88

Therapeutic monoclonal antibodies for COVID-19 management: an update

Chavda, V. P., Prajapati, R., Lathigara, D., Nagar, B., Kukadiya, J., Redwan, E. M. M. M., Uversky, V. N., Kher, M. N., & Patel, R. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2078160 · Cited by 74

Subtypes and Mimics of Sepsis

Kellum, J. A., Formeck, C. L., Kernan, K. F., Gómez, H., & Carcillo, J. A. (2022) · Critical Care Clinics · doi:10.1016/j.ccc.2021.11.013 · Cited by 62

Practicing With Uncertainty: Kidney Transplantation During the COVID-19 Pandemic

Lentine, K. L., Mannon, R. B., & Josephson, M. A. (2020) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2020.12.003 · Cited by 49

Dengue and severe dengue

Kalimuddin, S., Chia, P. Y., Low, J. G. H., & Ooi, E. E. (2025) · Clinical Microbiology Reviews · doi:10.1128/cmr.00244-24 · Cited by 50

A digital protein microarray for COVID-19 cytokine storm monitoring

Song, Y., Ye, Y., Su, S., Stephens, A., Cai, T., Chung, M. T., Han, M. K., Newstead, M. W., Yessayan, L., Frame, D. G., et al. (2020) · Lab on a Chip · doi:10.1039/d0lc00678e · Cited by 44

Efficacy of COVID-19 Treatments: A Bayesian Network Meta-Analysis of Randomized Controlled Trials

Zhang, C., Jin, H., Wen, Y. F., & Yin, G. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.729559 · Cited by 44

Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group

Hermine, O., Mariette, X., Porcher, R., Resche‐Rigon, M., Tharaux, P., & Ravaud, P. (2022) · European Respiratory Journal · doi:10.1183/13993003.02523-2021 · Cited by 41

The AI-Assisted Identification and Clinical Efficacy of Baricitinib in the Treatment of COVID-19

Richardson, P. J., Robinson, B. W. S., Smith, D. P., & Stebbing, J. (2022) · Vaccines · doi:10.3390/vaccines10060951 · Cited by 44

2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19

Alunno, A., Najm, A., Machado, P., Bertheussen, H., Burmester, G. R., Carubbi, F., Marco, G. D., Giacomelli, R., Hermine, O., Isaacs, J. D., et al. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-221366 · Cited by 39

Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants

Strohl, W. R., Ku, Z., An, Z., Carroll, S. F., Keyt, B. A., & Strohl, L. M. (2022) · BioDrugs · doi:10.1007/s40259-022-00529-7 · Cited by 35

Skeletal Muscle in Hypoxia and Inflammation: Insights on the COVID-19 Pandemic

Girolamo, F. G. D., Fiotti, N., Sisto, U. G., Nunnari, A., Colla, S., Mearelli, F., Vinci, P., Schincariol, P., & Biolo, G. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.865402 · Cited by 42

Angiopathic activity of LRG1 is induced by the IL-6/STAT3 pathway

Dritsoula, A., Dowsett, L., Pilotti, C., O’Connor, M. N., Moss, S. E., & Greenwood, J. (2022) · Scientific Reports · doi:10.1038/s41598-022-08516-2 · Cited by 37

Use of tocilizumab and sarilumab alone or in combination with corticosteroids for covid-19: systematic review and network meta-analysis

Zeraatkar, D., Cusano, E., Martinez, J. P. D., Qasim, A., Mangala, S., Kum, E., Bartoszko, J. J., Devji, T., Agoritsas, T., Guyatt, G. H., et al. (2022) · BMJ Medicine · doi:10.1136/bmjmed-2021-000036 · Cited by 37

Simultaneous Targeting of IL-1–Signaling and IL-6–Trans-Signaling Preserves Human Pulmonary Endothelial Barrier Function During a Cytokine Storm—Brief Report

Colás-Algora, N., Muñoz-Pinillos, P., Cacho-Navas, C., Ortiz, J. A., de Rivas, G., Barroso, S., López‐Collazo, E., & Millán, J. (2023) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.123.319695 · Cited by 33

Transcriptional response modules characterize IL-1β and IL-6 activity in COVID-19

Bell, L. C. K., Meydan, C., Kim, J., Foox, J., Butler, D., Mason, C. E., Shapira, S. D., Noursadeghi, M., & Pollara, G. (2020) · iScience · doi:10.1016/j.isci.2020.101896 · Cited by 32

Epigenetic perspectives associated with COVID-19 infection and related cytokine storm: an updated review

Dey, A., Vaishak, K., Deka, D., Radhakrishnan, A., Paul, S., Shanmugam, P., Selvabai, R. A. P., Pathak, S., Duttaroy, A. K., & Banerjee, A. (2023) · Infection · doi:10.1007/s15010-023-02017-8 · Cited by 34

Interactions of Influenza and SARS-CoV-2 with the Lung Endothelium: Similarities, Differences, and Implications for Therapy

Latreille, E., & Lee, W. L. (2021) · Viruses · doi:10.3390/v13020161 · Cited by 31

Bowel ischemia in COVID‐19: A systematic review

Patel, S., Parikh, C., Verma, D., Sundararajan, R., Agrawal, U., Bheemisetty, N., Akku, R., Sánchez‐Velazco, D., & Waleed, M. S. (2021) · International Journal of Clinical Practice · doi:10.1111/ijcp.14930 · Cited by 31

Beyond Vaccines: Clinical Status of Prospective COVID-19 Therapeutics

Kumar, S., Çalışkan, D. M., Janowski, J., Faist, A., Conrad, B. C. G., Lange, J., Ludwig, S., & Brunotte, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.752227 · Cited by 28

Serum Ferritin as a Predictor of Outcomes in Hospitalized Patients with Covid-19 Pneumonia

Shakaroun, D., Lazar, M. H., Horowitz, J. C., & Jennings, J. H. (2022) · Journal of Intensive Care Medicine · doi:10.1177/08850666221113252 · Cited by 28

Clinical phenotyping uncovers heterogeneous associations between corticosteroid treatment and survival in critically ill COVID-19 patients

Bruse, N., Motos, A., van Amstel, R. B. E., Bie, E. M. D. D. D., Kooistra, E. J., Jansen, A., van Lier, D. P. T., Kennedy, J. N., Schwarzkopf, D., Thomas-Rüddel, D. O., et al. (2024) · Intensive Care Medicine · doi:10.1007/s00134-024-07593-3 · Cited by 27

Tocilizumab plus dexamethasone versus dexamethasone in patients with moderate-to-severe COVID-19 pneumonia: A randomised clinical trial from the CORIMUNO-19 study group

Hermine, O., Xavier Mariette, A., Porcher, R., Djossou, F., Nguyen, Y., Arlet, J., Savale, L., Diehl, J., Georgin‐Lavialle, S., Cadranel, J. L., et al. (2022) · EClinicalMedicine · doi:10.1016/j.eclinm.2022.101362 · Cited by 25

Efficacy and safety of early soluble urokinase plasminogen receptor plasma-guided anakinra treatment of COVID-19 pneumonia: a subgroup analysis of the SAVE-MORE randomised trial

Akinosoglou, K., Kotsaki, A., Gounaridi, M. I., Christaki, E., Metallidis, S., Adamis, G., Fragkou, A., Fantoni, M., Rapti, A., Kalomenidis, I., et al. (2022) · EClinicalMedicine · doi:10.1016/j.eclinm.2022.101785 · Cited by 24

Tocilizumab in Patients Hospitalized with COVID-19 Pneumonia: Systematic Review and Meta-Analysis of Randomized Controlled Trials

Gupta, S., Padappayil, R. P., Bansal, A., Daouk, S., & Brown, B. R. (2021) · Journal of Investigative Medicine · doi:10.1136/jim-2021-002001 · Cited by 24

Is there a place for mesenchymal stromal cell-based therapies in the therapeutic armamentarium against COVID-19?

da Silva, K. N., Gobatto, A. L. N., Costa‐Ferro, Z. S. M., Cavalcante, B. R. R., Caria, A. C. I., França, L. S. D. A., Nonaka, C. K. V., Lima, F. D. M., Lopes‐Pacheco, M., Rocco, P. R. M., et al. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02502-7 · Cited by 22

Tocilizumab-coated solid lipid nanoparticles loaded with cannabidiol as a novel drug delivery strategy for treating COVID-19: A review

Zielińska, A., Eder, P., Karczewski, J., Szalata, M., Hryhorowicz, S., Wielgus, K., Szalata, M., Dobrowolska, A., Atanasov, A. G., Słomski, R., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1147991 · Cited by 22

COVID-19, what could sepsis, severe acute pancreatitis, gender differences, and aging teach us?

Gallo, C. G., Fiorino, S., Posabella, G., Antonacci, D., Tropeano, A., Pausini, E., Pausini, C., Guarniero, T., Hong, W., Giampieri, E., et al. (2021) · Cytokine · doi:10.1016/j.cyto.2021.155628 · Cited by 17

Immunomodulatory therapies for COVID-19

Mathur, P., & Kottilil, S. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.921452 · Cited by 17

Tocilizumab in patients with COVID-19: which patient, time, and dose?

Hasanin, A. M., & Mostafa, M. M. A. (2021) · Journal of Anesthesia · doi:10.1007/s00540-021-02974-0 · Cited by 15

Hyperhemolysis in a patient with sickle cell disease and recent SARS‐CoV ‐2 infection, with complex auto‐ and alloantibody work‐up, successfully treated with tocilizumab

Fuja, C., Kothary, V., Carll, T. C., Singh, S., Mansfield, P., & Wool, G. D. (2022) · Transfusion · doi:10.1111/trf.16932 · Cited by 14

IgG anti-RBD levels during 8-month follow-up post-vaccination with BNT162b2 and mRNA-1273 vaccines in healthcare workers: A one-center study

Gil-Manso, S., Alonso, R., Catalán, P., Sánchez-Arcilla, I., Marzola, M., Correa‐Rocha, R., Pion, M., Muñóz, P., & Gregorio Marañón Microbiology-ID COVID-19 Study Group (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.1035155 · Cited by 14

C reactive protein utilisation, a biomarker for early COVID-19 treatment, improves lenzilumab efficacy: results from the randomised phase 3 ‘LIVE-AIR’ trial

Temesgen, Z., Kelley, C. F., Cerasoli, F., Kilcoyne, A., Chappell, D. B., Durrant, C., Ahmed, O., Chappell, G., Catterson, V. M., Polk, C. M., et al. (2022) · Thorax · doi:10.1136/thoraxjnl-2022-218744 · Cited by 13

Sarilumab treatment of hospitalised patients with severe or critical COVID-19: a multinational, randomised, adaptive, phase 3, double-blind, placebo-controlled trialPreprint

Lescure, F.-X., Honda, H., Fowler, R., Lazar, J. S., Shi, G., Wung, P. K., Patel, N. R., & HAGINO, O. R. (2021) · medRxiv · doi:10.1101/2021.02.01.21250769 · Cited by 13

C-reactive protein cut-off for early tocilizumab and dexamethasone prescription in hospitalized patients with COVID-19

Camon, A. M., Alonso, R., Muñoz, F. J. T., Cardozo, C., Bernal-Maurandi, J., Albiach, L., Agüero, D. L., Marcos, M. Á., Ambrosioni, J., Bodro, M., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-08882-x · Cited by 13

Immunomodulatory therapies for the treatment of SARS-CoV-2 infection: an update of the systematic literature review to inform EULAR points to consider

Alunno, A., Najm, A., Mariette, X., Marco, G. D., Emmel, J., Mason, L., McGonagle, D., & Machado, P. (2021) · RMD Open · doi:10.1136/rmdopen-2021-001899 · Cited by 11

Role of cytokine storm in coronavirus infections: culprit or accomplice?

Xu, R., Liu, C., Xu, X., Hu, Y., Zhu, B., & Yang, C. (2022) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2703102 · Cited by 10

Abrogation of neutrophil inflammatory pathways and potential reduction of neutrophil-related factors in COVID-19 by intravenous immunoglobulin

Masso-Silva, J. A., Sakoulas, G., Olay, J., Groysberg, V. M., Geriak, M., Nizet, V., Alexander, L. E. C., & Meier, A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.993720 · Cited by 10

The COVID‐19 Menace

Walczak, P., & Janowski, M. (2021) · Global Challenges · doi:10.1002/gch2.202100004 · Cited by 9

Tocilizumab for COVID-19: A systematic review and meta-analysis of randomized controlled trials

Boppana, T. K., Mittal, S., Madan, K., Mohan, A., Hadda, V., & Guleria, R. (2022) · Monaldi Archives for Chest Disease · doi:10.4081/monaldi.2022.2136 · Cited by 10

Targeting cytokine storm as the potential anti-viral therapy: Implications in regulating SARS-CoV-2 pathogenicity

Maity, S., Santra, A., Hebbani, A. V., Pulakuntla, S., Chatterjee, A., Badri, K. R., & Reddy, V. D. (2023) · Gene · doi:10.1016/j.gene.2023.147612 · Cited by 9

Intra-pleural and intra-peritoneal tocilizumab therapy for managing malignant pleural effusions and ascites: The Regional Immuno-Oncology Trial (RIOT)−2 study protocol

Park, H., Lewis, C. M., Dadgar, N., Sherry, C., Evans, S., Ziobert, S., Omstead, A. N., Zaidi, A. H., Xiao, K., Ghosh, S., et al. (2024) · Surgical Oncology Insight · doi:10.1016/j.soi.2024.100045 · Cited by 9

A comparison between virus- versus patients-centred therapeutic attempts to reduce COVID-19 mortality

Camelo, S., Latil, M., Agus, S., Dioh, W., Veillet, S., Lafont, R., & Dilda, P. J. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.2006579 · Cited by 9

Trends in characteristics and outcomes among US adults hospitalised with COVID-19 throughout 2020: an observational cohort study

Page, J. H., Londhe, A. A., Brooks, C. G., Zhang, J., Sprafka, J. M., Bennett, C., Braunlin, M., Brown, C., Charuworn, P., Cheng, A., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-055137 · Cited by 9

How We Have Treated Severe to Critically Ill Patients With Coronavirus Disease 2019 in Korea

Park, D. H., Kang, C. K., Choe, P. G., Kim, N. J., Park, W. B., & Oh, M. (2022) · Journal of Korean Medical Science · doi:10.3346/jkms.2022.37.e353 · Cited by 9

High-CBD cannabis extracts inhibit the expression of proinflammatory factors via miRNA-mediated silencing in human small intestinal epithelial cells

Wang, B., Li, D., Fiselier, A., Kovalchuk, I., & Kovalchuk, O. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e18817 · Cited by 8

Topoisomerase 1 inhibition therapy protects against SARS-CoV-2-induced inflammation and death in animal modelsPreprint

Ho, J., Mok, B. W.-Y., Campisi, L., Jordan, T. X., Yildiz, S., Parameswaran, S., Wayman, J. A., Gaudreault, N. N., Meekins, D. A., Indran, S. V., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.12.01.404483 · Cited by 8

Tocilizumab-treated convalescent COVID-19 patients retain the cross-neutralization potential against SARS-CoV-2 variants

Chauvin, C., Levillayer, L., Roumier, M., Nielly, H., Roth, C., Karnam, A., Bonam, S. R., Bourgarit, A., Dubost, C., Bousquet, A., et al. (2023) · iScience · doi:10.1016/j.isci.2023.106124 · Cited by 7

COVID-19 Pneumonia and Cytokine Storm Syndrome

van de Veerdonk, F. L. (2024) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-59815-9_22 · Cited by 9

Review of Anti-inflammatory and Antiviral Therapeutics for Hospitalized Patients Infected with Severe Acute Respiratory Syndrome Coronavirus 2

Chen, J., & Ostermann, M. (2022) · Critical Care Clinics · doi:10.1016/j.ccc.2022.02.002 · Cited by 10

COVID-19 subphenotypes at hospital admission are associated with mortality: a cross-sectional study

Dubowski, K., Braganza, G. T., Bozack, A. K., Colicino, E., DeFelice, N., McGuinn, L. A., Maru, D., & Lee, A. (2022) · Annals of Medicine · doi:10.1080/07853890.2022.2148733 · Cited by 7

Treatment options for patients with severe COVID-19

Morishita, M., & Hojo, M. (2023) · Global Health & Medicine · doi:10.35772/ghm.2023.01024 · Cited by 8

A pilot phase Ib/II study of whole-lung low dose radiation therapy (LDRT) for the treatment of severe COVID-19 pneumonia: First experience from Africa

Saleh, M. N., Sharma, K., Shah, J., Karsan, F., Waweru, A., Musumbi, M., Shah, R., Sayed, S., Abayo, I., Karimi, N., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0270594 · Cited by 7

Highly multiplexed cytokine analysis of bronchoalveolar lavage and plasma reveals age-related dynamics and correlates of inflammation in children

Shanthikumar, S., Gubbels, L., Davies, K., Walker, H., Wong, A. T. C., Levi, E., Saffery, R., Ranganathan, S., & Neeland, M. R. (2024) · Mucosal Immunology · doi:10.1016/j.mucimm.2024.12.008 · Cited by 5

Global maternal mortality associated with SARS-CoV-2 infection: a systematic review and meta-analysis

Barry, K., Fernández-García, S., Khashaba, A., Ruiz‐Calvo, G., Redín, M. R., Mahmoud, G., Yap, M., King, Y., Zhou, D., Mamey, M., et al. (2025) · BMJ Global Health · doi:10.1136/bmjgh-2024-015815 · Cited by 5

Nosocomial Infections in COVID-19 Patients Treated with Immunomodulators: A Narrative Review

Ramasamy, C., Narayan, G., Mishra, A. K., John, K., & Lal, A. (2022) · Frontiers in Bioscience-Scholar · doi:10.31083/j.fbs1404026 · Cited by 5

The COVID-19 Pandemic and Adult Cardiac Transplantation: Impact, Interventions, and Implications

Chih, S., Clarke, B. A., Albert, M., Buchan, C. A., Kafil, T. S., Kim, D. H., Kumar, D., Smith, S. J., Solera, J. T., Stubbs, M. J., et al. (2023) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2023.03.014 · Cited by 5

Modeling mechanisms underlying differential inflammatory responses to COVID-19 in type 2 diabetes using a patient-derived microphysiological organ-on-a-chip system

Negi, V., Gavlock, D. C., Miedel, M. T., Lee, J. K., Shun, T., Gough, A., Vernetti, L. A., Stern, A. M., Taylor, D. L., & Yechoor, V. K. (2023) · Lab on a Chip · doi:10.1039/d3lc00285c · Cited by 6

Efficacy and Safety of Tocilizumab Treatment COVID-19 Patients: A Case-Control Study and Meta-Analysis

Jiang, W., Li, W., Wu, Q., Han, Y., Zhang, J., Luo, T., Guo, Y., Yang, Y., Zhu, P., & Xia, X. (2021) · Infectious Diseases and Therapy · doi:10.1007/s40121-021-00483-x · Cited by 5

Immunomodulatory therapy for the management of critically ill patients with COVID-19: A narrative review

Andaluz‐Ojeda, D., Vidal, P., Sanz, Á. A., Suberviola, B., Carbajo, L. D. R., Martín, L. N., Silva, E. P., Olmo, J. N.-D., Barberán, J., & Cusácovich, I. (2022) · World Journal of Critical Care Medicine · doi:10.5492/wjccm.v11.i4.269 · Cited by 6

Real-Life Use of Tocilizumab in the Treatment of Severe COVID-19 Pneumonia

Alex, R., Gulam, S. M., & Kumar, K. (2022) · Advances in Virology · doi:10.1155/2022/7060466 · Cited by 4

Improved COVID-19 outcomes in CAR-T patients in the age of vaccination and preemptive pharmacotherapeutics

Cheok, K. P. L., Kirkwood, A. A., Creasey, T., Tholouli, E., Chaganti, S., Mathew, A., Dulobdas, V., Irvine, D. A., Besley, C., Neil, L., et al. (2023) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2023.2248329 · Cited by 4

Interleukin-6 blocking therapy for COVID-19: From immune pathogenesis to clinical outcomes

Xiao, F., Wu, L., Zhu, X., Zhang, L., Liu, D. J., Wu, L., Zou, H., & Lu, L. (2022) · Rheumatology and Immunology Research · doi:10.2478/rir-2022-0002 · Cited by 4

COVID-19: individual and herd immunity

Bach, J., Berche, P., Chatenoud, L., Costagliola, D. G., & Valleron, A. (2021) · Comptes Rendus Biologies · doi:10.5802/crbiol.41 · Cited by 4

Case report: Disseminated herpes simplex virus 1 infection and hemophagocytic lymphohistiocytosis after immunomodulatory therapy in a patient with coronavirus disease 2019

Mazzotta, E. A., Fiorda‐Diaz, J., Echeverria-Villalobos, M., Eisinger, G. J., Sprauer, S., Singha, A., & Lyaker, M. R. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1053012 · Cited by 4

Do All Critically Ill Patients with COVID-19 Disease Benefit from Adding Tocilizumab to Glucocorticoids? A Retrospective Cohort Study

Mussini, C., Cozzi‐Lepri, A., Meschiari, M., Franceschini, E., Burastero, G. J., Faltoni, M., Franceschi, G., Iadisernia, V., Volpi, S., Dessilani, A., et al. (2023) · Viruses · doi:10.3390/v15020294 · Cited by 4

Drug repurposing for respiratory infections

Israr, J., Alam, S., & Kumar, A. (2024) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2024.03.033 · Cited by 3

A multimodal atlas of COVID-19 severity identifies hallmarks of dysregulated immunity 2258066

Slowikowski, K., Sen, P., Cosgriff, C. V., Tantivit, J., Eisenhaure, T., LaSalle, T. J., Manakongtreecheep, K., Tirard, A. J., Arnold, B. Y., Pacheco-Navarro, A. E., et al. (2026) · The Journal of Immunology · doi:10.1093/jimmun/vkag141.533 · Cited by 3

Real‐World Evidence to Supplement Randomized Clinical Trials: Tocilizumab for Severe COVID ‐19 Pneumonia vs. a Cohort Receiving Standard of Care

Skarbinski, J., Fischer, H. J., Hong, V. X., Liu, L., Yau, V., Incerti, D., Qian, L., Ackerson, B. K., Amsden, L. B., Shaw, S. F., et al. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3020 · Cited by 3

Hypothesis-Agnostic Network-Based Analysis of Real-World Data Suggests Ondansetron is Associated with Lower COVID-19 Any Cause Mortality

Miller, G. M., Ellis, J. A., Sarangarajan, R., Parikh, A., Rodrigues, L. O., Bruce, C., Chand, N. M., Smith, S. R., Richardson, K., Vazquez, R., et al. (2022) · Drugs - Real World Outcomes · doi:10.1007/s40801-022-00303-9 · Cited by 3

Early Multidrug Treatment of SARS-Cov-2 (COVID-19) and Decreased Case Fatality Rates in Honduras

Ontai, S. C., Zeng, L., Hoffman, M. S., Pascua, F. V., VanBuren, V., & McCullough, P. A. (2022) · Epidemiology International Journal · doi:10.23880/eij-16000217 · Cited by 3

Application of LRG mechanism in normal pressure hydrocephalus

Ma, L., Wang, W., Zhao, Y., Liu, M., Ye, W., & Li, X. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e23940 · Cited by 4

The clinical features, treatment and prognosis of neutropenic fever and Coronavirus disease 2019 results of the multicentre teos study

Elik, D. B., Kaya, Ş., Alkan, S., Demırdal, T., Şener, A., Kaya, S., Tunçcan, Ö. G., Kayaaslan, B., Güner, R., Eser, F., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-55886-w · Cited by 5

Tocilizumab demonstrates superiority in decreasing C-reactive protein levels in hospitalized COVID-19 patients, compared to standard care treatment alone

Calderón-Ochoa, C., Plamenov-Donchev, N., Hernández-Quiñones, F., Mendoza-López, O., Hinojos-Gallardo, L. C., Longino-Gómez, A. J., Hernández-Saldaña, R., Duque-Rodríguez, J., & Ishida-Gutiérrez, M. C. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.02498-23 · Cited by 3

Tocilizumab, blood cells, and mild COVID-19: delayed vascular protection by interleukin blockade?

Buryachkovskaya, L. I., Lomakin, N. V., Melkumyants, A. M., Docenko, J., & Serebruany, V. L. (2021) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvab051 · Cited by 3

Drugs repurposing for SARS-CoV-2: new insight of COVID-19 druggability

Debnath, S. K., Debnath, M., Srivastava, R., & Omri, A. (2022) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2022.2082944 · Cited by 3

Interleukin-6 inhibitors: from the therapy of immuno-inflammatory rheumatic diseases to use in COVID-19

Muravyeva, N., & Belov, B. (2022) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2022-16-11-88-94

The use of tocilizumab in severe COVID-19: A comprehensive review

Milošević, I., & Beronja, B. (2024) · Medicinska istrazivanja · doi:10.5937/medi57-48405 · Cited by 2

Efficacy of Single Tocilizumab Administration in an 88-Year-Old Patient with Severe COVID-19 and a Mini Literature Review

Ouali, C. O., Ladjouzi, N., Tamas, K., Raveloson, H., Hassen, J. B., Omeiri, N. E., Zouloumis, G., Zoabi, M. M. A., Asadi, M., Jhouri, A., et al. (2022) · Geriatrics · doi:10.3390/geriatrics7010022 · Cited by 2

Inhaled beclomethasone in the treatment of early COVID-19: a double-blind, placebo-controlled, randomised, hospital-based trial in Sri Lanka

Mettananda, C. D., Peiris, C., Abeyrathna, D., Gunasekara, A., Egodage, T., Dantanarayana, C., Pathmeswaran, A., & Ranasinha, C. D. (2023) · BMJ Open · doi:10.1136/bmjopen-2023-075803 · Cited by 2

Tocilizumab in COVID-19 management: addressing time of starting treatment

Khiali, S., & Entezari‐Maleki, T. (2022) · European Journal of Hospital Pharmacy · doi:10.1136/ejhpharm-2021-003149 · Cited by 2

Levels of circulating kidney injury markers and IL-10 identify non-critically ill patients with COVID-19 at risk of death

Lenoir, O., Morin, F., Walter‐Petrich, A., Resmini, L., Zaidan, M., Mahtal, N., Ferlicot, S., Puelles, V. G., Wanner, N., Dang, J., et al. (2026) · JCI Insight · doi:10.1172/jci.insight.198244 · Cited by 1

Pharmacotherapy for COVID-19: A Ray of Hope

Kapoor, M., Panda, P. K., & Mohanty, V. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.97012 · Cited by 1

Clinical and radiologic outcomes in two patients with multiple sclerosis treated with tocilizumab for COVID-19

Holroyd, K. B., Conway, S. E., Bhattacharyya, S., & Galetta, K. M. (2022) · Neuroimmunology Reports · doi:10.1016/j.nerep.2022.100061 · Cited by 1

A novel logical model of COVID-19 intracellular infection to support therapies development

Piretto, E., Selvaggio, G., Bragantini, D., Domenici, E., & Marchetti, L. (2022) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1010443 · Cited by 1

Immunosuppressive drugs and their aerosol delivery for COVID-19 treatment

Kobylyansky, V. I. (2022) · Fundamental and Clinical Medicine · doi:10.23946/2500-0764-2022-7-3-74-84 · Cited by 1

Interventions reducing mortality in COVID-19 patients: a systematic review of randomized evidence

Maimeri, N., Marmiere, M., Losiggio, R., Nardelli, P., Redaelli, M. B., Fresilli, S., D’Amico, F., Zangrillo, A., Hajjar, L. A., & Landoni, G. (2023) · Minerva Medica · doi:10.23736/s0026-4806.23.08590-7 · Cited by 1

Tocilizumab in ICU-admitted COVID-19 Patients: A Retrospective Study

Siami, Z., Yaghoobi, M. H., & Karimi, P. (2023) · Medical Journal of the Islamic Republic of Iran · doi:10.47176/mjiri.37.92 · Cited by 1

A systematic review and meta-analysis of the safety of anti-interleukin therapy in COVID-19

Gomon, Y. М., Колбин, А. С., Strizheletsky, V. V., Ivanov, I., Sultanova, F. М., & Balykina, Y. Е. (2022) · Clinical Microbiology and Antimicrobial Chemotherapy · doi:10.36488/cmac.2022.2.93-107 · Cited by 1

“L’histoire se répète”, one size does not fit all

Kuindersma, M., & Spronk, P. E. (2021) · Intensive Care Medicine · doi:10.1007/s00134-021-06483-2 · Cited by 1

Factors Associated with The Speed and Scope of Diffusion of COVID-19 Therapeutics in a Nationwide Healthcare Setting: A Mixed Methods InvestigationPreprint

La, J., Fillmore, N. R., Do, N., Brophy, M. T., Monach, P. A., & Branch‐Elliman, W. (2022) · Research Square · doi:10.21203/rs.3.rs-1899144/v2 · Cited by 1

Tocilizumab in COVID-19: Is the Temptation Worthwhile?

Gupta, S., & Tomar, D. S. (2021) · Indian Journal of Critical Care Medicine · doi:10.5005/jp-journals-10071-23750

COVID-19 TEDAVİSİNDE İLAÇ-İLAÇ ETKİLEŞİMLERİNİN FARMAKOKİNETİK AÇIDAN DEĞERLENDİRİLMESİ

COŞKUN, N., & Lalegül‐Ülker, Ö. (2021) · Ankara Universitesi Eczacilik Fakultesi Dergisi · doi:10.33483/jfpau.881317

Tocilizumab and SARS-CoV-2 (COVID-19): An Evolving Story, the Picture Is Clearer

Bush, L. M., Williams, J., & Stutchin, E. (2021) · Infectious Diseases in Clinical Practice · doi:10.1097/ipc.0000000000001063

Analysis of Serial C-Reactive Protein Levels in Critically Ill COVID-19 Patients Receiving Tocilizumab

Masood, A., Farooq, O., Waris, S., Khan, M. Z., Mumtaz, A., Aslam, M., & Usama, M. (2020) · BIOMEDICA · doi:10.24911/biomedica/5-132 · Cited by 1

Tocilizumab demonstrates superiority in decreasing C-reactive protein levels in hospitalized COVID-19 patients, compared to standard care treatment alone

Calderón-Ochoa, C., Plamenov-Donchev, N., Hernández-Quiñones, F., Mendoza-López, O., Hinojos-Gallardo, L. C., Longino-Gómez, A. J., Hernández-Saldaña, R., Duque-Rodríguez, J., & Ishida-Gutiérrez, M. C. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.02498-23 · Cited by 3

Tocilizumab in hospitalized patients with COVID‐19: Clinical outcomes, inflammatory marker kinetics, and safety

Hill, J. A., Menon, M. P., Dhanireddy, S., Wurfel, M. M., Green, M., Jain, R., Chan, J. D., Huang, J., Bethune, D., Turtle, C. J., et al. (2020) · Journal of Medical Virology · doi:10.1002/jmv.26674 · Cited by 33

Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019

Price, C. C., Altice, F. L., Shyr, Y., Koff, A., Pischel, L., Goshua, G., Azar, M. M., McManus, D. S., Chen, S., Gleeson, S. E., et al. (2020) · CHEST Journal · doi:10.1016/j.chest.2020.06.006 · Cited by 204

Effects of tocilizumab on mortality in hospitalized patients with COVID-19: a multicentre cohort study

Martínez‐Sanz, J., Muriel, A., Ron, R., Herrera, S., Pérez-Molina, J. A., Moreno, S., & Villar, S. S. (2020) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2020.09.021 · Cited by 105